Author

Hamsa L.S. Kumar

Observed name: Hamsa L. S. Kumar

Institutions: University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University

Observed institutions: University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University

OpenAlex ID: A5127818276

Variant allele frequency as a potential marker in response to frontline systemic therapy for patients with locally advanced and metastatic urothelial carcinoma

2026 · Albert Jang, Sulin Wu, et al. · Translational Andrology and Urology

EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).

2026 · Albert Jang, Peggy Fowler, et al. · Journal of Clinical Oncology

Integrating circulating tumor DNA (ctDNA) and TP53 alteration variant allele frequency (VAF) to predict outcomes in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV).

2026 · Abby Grier, Albert Jang, et al. · Journal of Clinical Oncology

Works count: 3

Citation count:

H-index:

I10-index: